BOSTON & GENEVA--(BUSINESS WIRE)--Attendees at the 10th Annual PRO & eCOA Congress in Boston last month reaffirmed the need to use electronic clinical outcome assessment (COA) Systems as recommended by the FDA PRO Guidance to improve clinical research and gain regulatory approvals.
The PRO & eCOA Congress, hosted by PHT Corporation, is the premier PRO and eClinical outcome assessment meeting. It is attended by pharmaceutical and biotechnology professionals in clinical operations, outsourcing, data management, eClinical technologies, regulatory affairs, and health outcomes as well as PRO and eCOA thought leaders, regulators and sites.
Sheila Rocchio, MBA, PHT Vice President of Marketing and Product Management, said, “This year’s Congress set a new standard for the depth and level of knowledge, experience and insights shared by participants. It is absolutely clear from each presentation, workshop and roundtable discussion that eCOA technologies are the standard for enabling patient-centric clinical research that speeds the delivery of new drugs and therapies.”
For the first time in Congress history attendees heard the patient perspective. Renay Houle, Volunteer/Advocate for the Arthritis Foundation New England Region, shared her experience as a clinical research participant in a presentation, “The RA Patient Experience: Trials, Treatment & Life with Rheumatoid Arthritis.”
Kenneth A. Getz, Director of sponsored research programs at Tufts CSDD and the Founder of CenterWatch, keynoted the event with a presentation on the changing R&D paradigm and the critical need to engage patients as partners in pre- and post-approval studies. Other speakers included representatives from Biogen Idec, Celgene Corporation, Palatin Technologies, QualityMetric Inc. and PHT. Event sponsors were CenterWatch, Bluebird Inc., Lionbridge Life Sciences, Intel and Dell.
Also during the Congress customers learned how the PHT SitePad® System was used by a customer to achieve primary and secondary endpoints for studies of its drug which achieved FDA approval.
Next month PHT will launch a Patient-Centric Research Video Series to highlight Congress presentations, the future of the eCOA industry and the panel session led by Kenneth Getz with contributions from representatives of PatientsLikeMe, Biogen Idec, and Eli Lilly and Company, as well as PHT Founder Dr. Stephen Raymond. See how Congress attendees drove the discussion about eCOA Systems for improved clinical research, participated in educational sessions, shared experiences and enjoyed networking with peers: http://bit.ly/1qxtiQS
Registration is open for the PRO & eCOA Congress, Europe, 3-5 June in Barcelona, Spain. Learn more here: http://bit.ly/CongressBarcelona. The agenda combines presentations, case studies, workshops and roundtable discussions that focus on the latest PRO and eCOA innovations, case studies and best practices. PHT invites all Congress alumni to join the PRO & eCOA Congress LinkedIn Community to exchange information, ideas and experiences throughout the year.
Meet PHT at the Outsourcing in Clinical Trials Europe, 21-22 May to be entered to win one free PRO & eCOA Congress registration and hotel accommodation in Barcelona.
About PHT Corporation
PHT Corporation is the eClinical
innovator leading the adoption of patient-driven mobile apps for better
clinical research. The PHT electronic clinical outcome assessment (eCOA)
system collects and reports secure real-time patient data from the
latest mobile devices. PHT scientific, regulatory and technological
expertise combined with quality outcomes data enable clients to make
research decisions with confidence. Sponsors and CROs have leveraged the
PHT Patient Suite in 650+ trials resulting in 16+ regulatory approvals.
Visit phtcorp.com
for more information on PHT. Follow PHT on LinkedIn,
Twitter,
Google+
and YouTube.
